Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer combo therapy aims to shrink tumors before surgery

NCT ID NCT06088771

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests whether combining two drugs—dupilumab and cemiplimab—given before surgery can improve outcomes for people with early-stage non-small cell lung cancer. Participants receive one dose of each drug, then undergo standard surgery about two weeks later. Researchers monitor safety and how much the tumor shrinks, with follow-up for up to five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of dupilumab (Dupixent) and cemiplimab (Libtayo)
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with early-stage lung cancer.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply broadly. The combination may cause side effects or fail to improve response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.